TRPV3 is a central regulator in skin disease as it regulates proliferation, differentiation, and barrier function of human skin. It is involved in the development of severe palmoplantar keratoderma, periorificial hyperkeratotic plaques, diffuse alopecia, extreme pruritus, and pain.

Kamari pharma is dedicated to the development of novel TRPV3 inhibitors, targeting reduction of
hyperkeratosis, pain and severe chronic itch.

KM-001 – Topical treatment
KM-023 – Oral drug treatment

Kamari’s first in class propriety molecules are highly specific and selective TRPV3 inhibitors, that address both the molecular and local damage to the skin by regulating Ca²⁺ influx into the cell reconstructing skin barrier and reducing inflammation.